Wird geladen...

Molecular targeting of renal cell carcinoma by an oral combination

The 5-year survival rate of patients with metastatic renal cell carcinoma (mRCC) is <12% due to treatment failure. Therapeutic strategies that overcome resistance to modestly effective drugs for mRCC, such as sorafenib (SF), could improve outcome in mRCC patients. SF is terminally biotransformed...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogenesis
Hauptverfasser: Jordan, Andre R., Wang, Jiaojiao, Yates, Travis J., Hasanali, Sarrah L., Lokeshwar, Soum D., Morera, Daley S., Shamaladevi, Nagarajarao, Li, Charles S., Klaassen, Zachary, Terris, Martha K., Thangaraju, Muthusamy, Singh, Amar B., Soloway, Mark S., Lokeshwar, Vinata B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2020
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7237463/
https://ncbi.nlm.nih.gov/pubmed/32427869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-020-0233-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!